In concordance with our clinical observation of ENTPD2 overexpression, we further showed that NT5E inhibitor could not prevent the 5′-AMP-induced MDSC maintenance, suggesting that ENTPD2 but not NT5E is critical for MDSC maintenance in the context of cancer. The gene discussed is ENTPD2; the disease is cancer.